 Upon dosing, Principia will be entitled to a 50 million milestone payment. SAR442168, discovered by Principia and formerly known as PRN2246, is a Brutons tyrosine kinase BTK inhibitor that crosses the human blood-brain barrier and modulates immune cell function in both the periphery and in the central nervous system CNS, which shows promise for the potential treatment of CNS diseases. 